Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Kamada
Deal Size : Undisclosed
Deal Type : Agreement
Details : The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products...
Product Name : Kedrab
Product Type : Vaccine
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Kamada
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Kedrion IVIG
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study
Details : The primary efficacy objective of KIDCARES10 is to assess the efficacy of KIg10 administered to patients with PI to demonstrate that the rate of acute serious bacterial infections is less than 1.0 to provide substantial evidence of efficacy from day 1 to...
Product Name : KIg10
Product Type : Antibody
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : Kedrion IVIG
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Kedrion IVIG
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KIDCARES10, First Patient Enrolled in Pediatric PI Study
Details : Objectives of KIDCARES10 Study, a phase III, multi-center study are to assess the efficacy, safety, and pharmacokinetics of a 10 percent intravenous immunoglobulin (IVIG) in pediatric patients aged 2 to 17 years and affected by primary immunodeficiency d...
Product Name : KIg10
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2021
Lead Product(s) : Kedrion IVIG
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Columbia University
Deal Size : Undisclosed
Deal Type : Partnership
Details : Kedrion will supply convalescent plasma from patients who have recovered from COVID-19 to be used for the manufacturing of IgG therapy. Columbia University will test the plasma against viral proteins to check the neutralizing power of the hyperimmune Im...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Columbia University
Deal Size : Undisclosed
Deal Type : Partnership